SillaJen to acquire rights for Basileas novel kinase inhibitor BAL0891
By, Admin1 min read
Share
Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company, announced that it has entered into an asset purchase agreement and a sub-license agreement with SillaJen, Inc. for Basilea
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
